<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393038</url>
  </required_header>
  <id_info>
    <org_study_id>ABX464-401</org_study_id>
    <nct_id>NCT04393038</nct_id>
  </id_info>
  <brief_title>ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19</brief_title>
  <acronym>Mir-Age</acronym>
  <official_title>A Phase 2/3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged ≥ 65 and Patients Aged ≥18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abivax S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abivax S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and
      the safety of ABX464 in treating inflammation and preventing acute respiratory failure in
      patients aged ≥65 and patients aged ≥18 with at least one additional risk factor who are
      infected with SARS-CoV-2 (the MiR-AGE study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2/3 study will evaluate the efficacy and safety of ABX464 50mg QD (oral capsule),
      on treating inflammation and preventing acute respiratory failure in patients infected with
      SARS-CoV-2.

      Eligible patients will be randomized according to a 2:1 ratio into 2 treatment cohorts as
      follows:

        -  Standard of Care + Placebo cohort: 344 patients

        -  Standard of Care + ABX464 50mg QD: 690 patients

      Study design:

      The study will consist of 2 periods:

        -  Treatment phase: randomized patients will be treated for 28 days

        -  Safety follow-up phase of 14 days after which the End of Study visit (EOS) will be
           performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2/3, randomized, double blind, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinded treatment bottles</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive</measure>
    <time_frame>at the end of the 28-day treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients hospitalized</measure>
    <time_frame>28-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reporting each severity rating on a 7-point ordinal scale</measure>
    <time_frame>28-day treatment period</time_frame>
    <description>7-point ordinal scale is defined as Not hospitalized, no limitations on activities; Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from enrolment in inflammatory markers in plasma and in immune phenotype and assessment of cell-activation markers in PBMCs</measure>
    <time_frame>at each study visit during the 28-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients requiring oxygen supplementation</measure>
    <time_frame>28-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospitalization</measure>
    <time_frame>28-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to assisted ventilation and oxygen supplementation</measure>
    <time_frame>28-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in microRNA-124 levels</measure>
    <time_frame>at each study visit during the 28-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CRP, Troponin I &amp; T and D-dimer</measure>
    <time_frame>at each study visit during the 28-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>at each study visit during the 28-day treatment period</time_frame>
    <description>Nasopharyngeal sample and/or in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and rates of participants with Treatment Emergent Adverse Event</measure>
    <time_frame>28-day treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1034</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>ABX464</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABX464 - Capsules + Standard of Care (SOC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - Capsules + Standard of Care (SOC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX464</intervention_name>
    <description>ABX464 50mg QD for 28 days + Standard of Care</description>
    <arm_group_label>ABX464</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 50mg QD for 28 days + Standard of Care</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (≥ 18 years old) men or women, hospitalized or not hospitalized, diagnosed for
             SARS-CoV-2 infection by PCR, with at least one associated risk factor. Considered risk
             factors are:

               -  Age ≥ 65 years

               -  Obesity defined as BMI ≥ 30

               -  Recent history of uncontrolled High Blood Pressure (SBP &gt; 150 mm Hg DBP &gt;100 mm
                  Hg) according to investigator

               -  Treated diabetes (type I or II)

               -  History of ischemic cardiovascular disease

          2. Symptomatic patients at enrollment. Symptoms are defined as fever (body temperature ≥
             37.8 C oral/tympanic, or ≥ 38.2 C rectal) for more than 24 hours associated either
             with headache, sore throat, dry cough, fatigue, chest pain or choking sensation (with
             no associated respiratory distress), myalgia, anosmia or ageusia.

          3. Patients with pulse oximetry arterial saturation ≥ 92 % on room air at enrolment.

          4. Patients with the following hematological and biochemical laboratory parameters
             obtained within 7 days prior to Day 0:

               -  Hemoglobin above 9.0 g / dL

               -  Absolute Neutrophil Count ≥ 1000 / mm3

               -  Platelets ≥ 100 000 mm3;

               -  Creatinine clearance ≥ 50 mL / min by the Cockcroft Gault formula

               -  Total serum bilirubin &lt; 2 x ULN

               -  Alkaline phosphatase &lt; 2 x ULN, AST (SGOT) and ALT (SGPT) &lt; 3 x ULN;

        Exclusion Criteria:

          1. Patients with moderate or severe acute respiratory failure or requiring noninvasive
             ventilation or oxygen or with SpO2 &lt; 92% or tachypnea (respiratory rate ≥ 30
             breaths/min).

          2. Patients treated with immunosuppressors and/or immunomodulators.

          3. Engrafted patients (organ and/or hematopoietic stem cells).

          4. Patients with uncontrolled auto-immune disease.

          5. Patients with known or suspected active (i.e. not controlled) bacterial, viral
             (excluding COVID-19) or fungal infections.

          6. Patients with preexisting, severe and not controlled organ failure.

          7. History or active malignancy requiring chemotherapy or radiation therapy (excluding 2
             years disease free survivor patients).

          8. Pregnant or breast-feeding women.

          9. Illicit drug or alcohol abuse or dependence that may compromise the patient's safety
             or adherence to the study protocol.

         10. Use of any investigational or non-registered product within 3 months or within 5
             half-lives preceding baseline, whichever is longer.

         11. Hypersensitivity to ABX464 and/or its excipients.

         12. Any condition, which in the opinion of the investigator, could compromise the
             patient's safety or adherence to the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric CUA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul GINESTE</last_name>
    <phone>+33 625830783</phone>
    <email>paul.gineste@abivax.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anais Vissian</last_name>
    <email>anais.vissian@abivax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier Saint Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - Instituto de Pesquisa Clínica Carlos Borborema</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <zip>69040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Roraima - CECOR - NAP</name>
      <address>
        <city>Boa Vista</city>
        <state>Roraima</state>
        <zip>69310-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Conjunto Hospitalar do Mandaqui</name>
      <address>
        <city>Sao Paulo</city>
        <zip>02401-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental de Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric CUA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Universitätsklinikum Bonn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico - Infectious Diseases</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco, AO-PU</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale di Vittorio Veneto - Medecina generale</name>
      <address>
        <city>Vittorio Veneto</city>
        <state>Treviso</state>
        <zip>31029</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Manzonidi Lecco - ASST Lecco</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consultorio médico</name>
      <address>
        <city>Mérida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Prevención y Rehabilitación de Enfermedades Pulmon</name>
      <address>
        <city>Nuevo León</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.G.U. Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>ABX464</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

